Simultaneous detection of 19 drugs of abuse on dried urine spot by liquid chromatography-tandem mass spectrometry

Clinical Biochemistry

Volumn 46, Issue 12, 2013, Pages 1118-1124

  Lee, Yungkang ^a   Lai, Keane K Y ^a,b,c,d   Sadrzadeh, S M Hossein ^a,e  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF CALGARY   (Canada)

Author keywords

Cost analysis; Cross reactivity; EMIT; Extraction; IMethod; LC MS MS; Reflex GC MS; SAMHSA

Indexed keywords

ACCURACY; ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRIED URINE SPOT; DRUG ABUSE; GAS CHROMATOGRAPHY; IMMUNOASSAY; LIQUID CHROMATOGRAPHY; PRESERVATION AND STORAGE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; TURNAROUND TIME; VALIDATION PROCESS;

CLINICAL AND LABORATORY STANDARDS INSTITUTE; CLSI; COEFFICIENT OF VARIATION; COST ANALYSIS; CROSS-REACTIVITY; CV; DAT; DRIED URINE SPOT; DRUG OF ABUSE TESTING; DUS; EMIT; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; EXTRACTION; FDA; FOOD AND DRUG ADMINISTRATION; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GC-MS; IMETHOD; LC-MS/MS; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; LLOQ; LOWER LIMIT OF QUANTIFICATION; QC; QUALITY CONTROL; REFLEX GC-MS; SAMHSA; SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION; ULOQ; UPPER LIMIT OF QUANTIFICATION;

CALIBRATION; CHROMATOGRAPHY, LIQUID; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; LIMIT OF DETECTION; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; STREET DRUGS; SUBSTANCE ABUSE DETECTION; TANDEM MASS SPECTROMETRY;

EID: 84880615897     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2013.03.027     Document Type: Article

References (19)

1. Eichhorst J.C., Etter M.L., Rousseaux N., Lehotay D.C. Drugs of abuse testing by tandem mass spectrometry: A rapid, simple method to replace immunoassays. Clin Biochem 2009, 42:1531-1542.
2. Peat M., Davis A.E. Analytical considerations and approaches for drugs. Drug Abuse Handbook 1998, CRC Press, Boca Baton, FL. S.B. Karch (Ed.).
3. Badawi N., Simonsen K.W., Steentoft A., Bernhoft I.M., Linnet K. Simultaneous screening and quantification of 29 drugs of abuse in oral fluid by solid-phase extraction and ultraperformance LC-MS/MS. Clin Chem 2009, 55:2004-2018.
4. de Castro A., Concheiro M., Shakleya D.M., Huestis M.A. Development and validation of a liquid chromatography mass spectrometry assay for the simultaneous quantification of methadone, cocaine, opiates and metabolites in human umbilical cord. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877:3065-3071.
5. Siuzdak G. The expanding role of mass spectrometry in biotechnology 2006, MCC Press, San Diego, CA. 2nd ed. G. Siuzdak (Ed.).
6. Rook E.J., Hillebrand M.J., Rosing H., van Ree J.M., Beijnen J.H. The quantitative analysis of heroin, methadone and their metabolites and the simultaneous detection of cocaine, acetylcodeine and their metabolites in human plasma by high-performance liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2005, 824:213-221.
7. Edelbroek P.M., van der Heijden J., Stolk L.M. Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls. Ther Drug Monit 2009, 31:327-336.
8. Keevil B.G. The analysis of dried blood spot samples using liquid chromatography tandem mass spectrometry. Clin Biochem 2011, 44:110-118.
9. Li W., Tse F.L. Dried blood spot sampling in combination with LC-MS/MS for quantitative analysis of small molecules. Biomed Chromatogr 2010, 24:49-65.
10. U.S.Department of Health and Human Services FaDA, Center for Drug Evaluation, Research (CDER), Center for Veterinary Medicine (CVM) Guidance for industry: bioanalytical method validation 2001.
11. Mass spectrometry in the clinical laboratory: general principles and guidance; approved guideline 2007, Clinical and Laboratory Standards Institute.
12. Mandatory guidelines for federal workplace drug testing programs; Federal Register November 25, 2008 (73 FR 71858) 2008, 71858-71907. The Substance Abuse and Mental Health Services Administration, (SAMHSA) (Eds.).
13. Mandatory guidelines for federal workplace drug testing programs; Federal Register April 30, 2010 (75 FR 22809) 2010, 22809-22810. The Substance Abuse and Mental Health Services Administration, (SAMHSA) (Eds.).
14. Verstraete A.G., Heyden F.V. Comparison of the sensitivity and specificity of six immunoassays for the detection of amphetamines in urine. J Anal Toxicol 2005, 29:359-364.
15. Feng J., Wang L., Dai I., Harmon T., Bernert J.T. Simultaneous determination of multiple drugs of abuse and relevant metabolites in urine by LC-MS-MS. J Anal Toxicol 2007, 31:359-368.
16. Yuan C., Heideloff C., Kozak M., Wang S. Simultaneous quantification of 19 drugs/metabolites in urine important for pain management by liquid chromatography-tandem mass spectrometry. Clin Chem Lab Med 2012, 50:95-103.
17. Meany D.L., Clarke W. Opiate dau screening using dried urine specimens. Clin Chim Acta 2009, 401:188-189.
18. Sasaki TA. Forensic technology widens net for drugs of abuse: The rise of LC/MS/MS for toxicology testing. Forensic Magazine 2007.
19. Lewandrowski K., Flood J., Finn C., Tannous B., Farris A.B., Benzer T.I., et al. Implementation of point-of-care rapid urine testing for drugs of abuse in the emergency department of an academic medical center: impact on test utilization and ED length of stay. Am J Clin Pathol 2008, 129:796-801.